ImmunoGen announced that Genentech has reported the FDA approval of Kadcyla (ado-trastuzumab emtansine) for the treatment of HER2-positive metastatic breast cancer in patients who have received prior treatment with Herceptin (trastuzumab; Genentech) and a taxane chemotherapy.
Trastuzumab emtansine is an antibody-drug conjugate (ADC) comprised of the antibody trastuzumab and the chemotherapy DM1 attached together using a stable linker. It is designed to target and inhibit HER2 signaling and deliver the chemotherapy directly inside HER2-positive cancer cells.
Kadcyla was granted priority review on November 2012. Genentech plans to launch Kadcyla soon.
For more information call (781) 895-0600 or visit www.immunogen.com
This article originally appeared on MPR